Abstract
Two human di / tri-peptide transporters, hPepT1 and hPepT2 have been identified and functionally characterized. In the small intestine hPepT1 is exclusively expressed, whereas both PepT1 and PepT2 are expressed in the proximal tubule. The transport via di / tri-peptide transporters is proton-dependent, and the transporters thus belong to the Proton-dependent Oligopeptide Transporter (POT)-family. The transporters are not drug targets per se, however due to their uniquely broad substrate specificity; they have proved to be relevant drug targets at the level of drug transport. Drug molecules such as oral active β-lactam antibiotics, bestatin, prodrugs of aciclovir and ganciclovir have oral bioavailabilities, which largely are a result of their interaction with PepT1. In the last few years an increasing number of studies concerned with regulation of di / tri-peptide transporter capacity have appeared. Studies on receptor-mediated regulation has shown that both PepT1 and PepT2 is down-regulated by long-term exposure to epidermal growth factor (EGF) due to a decreased gene transcription. PepT1-mediated transport is upregulated by certain substrates and in response to fasting and starvation at the level of increased gene transcription. PepT1-mediated transport is up-regulated by short-term exposure to receptor agonists such as EGF, insulin, leptin, and clonidine, and down-regulated by VIP. Overall, the regulation of di / tri-peptide transport may be contributed to 1) changes in apical proton-motive force 2) recruitment of di / tri-peptide transporters from vesicular storages 3) changes in gene transcription / mRNA stability. The aim of the present review is to discuss physiological, patho-physiological and druginduced regulation of di / tri-peptide transporter mediated transport.
Keywords: tri-peptide transporters, hpept1, hpept2, nhe3, epithelia, peptidomimetics, regulation
Current Drug Targets
Title: Di / tri-Peptide Transporters as Drug Delivery Targets: Regulation of Transport Under Physiological and Patho-physiological Conditions
Volume: 4 Issue: 5
Author(s): C. U. Nielsen and B. Brodin
Affiliation:
Keywords: tri-peptide transporters, hpept1, hpept2, nhe3, epithelia, peptidomimetics, regulation
Abstract: Two human di / tri-peptide transporters, hPepT1 and hPepT2 have been identified and functionally characterized. In the small intestine hPepT1 is exclusively expressed, whereas both PepT1 and PepT2 are expressed in the proximal tubule. The transport via di / tri-peptide transporters is proton-dependent, and the transporters thus belong to the Proton-dependent Oligopeptide Transporter (POT)-family. The transporters are not drug targets per se, however due to their uniquely broad substrate specificity; they have proved to be relevant drug targets at the level of drug transport. Drug molecules such as oral active β-lactam antibiotics, bestatin, prodrugs of aciclovir and ganciclovir have oral bioavailabilities, which largely are a result of their interaction with PepT1. In the last few years an increasing number of studies concerned with regulation of di / tri-peptide transporter capacity have appeared. Studies on receptor-mediated regulation has shown that both PepT1 and PepT2 is down-regulated by long-term exposure to epidermal growth factor (EGF) due to a decreased gene transcription. PepT1-mediated transport is upregulated by certain substrates and in response to fasting and starvation at the level of increased gene transcription. PepT1-mediated transport is up-regulated by short-term exposure to receptor agonists such as EGF, insulin, leptin, and clonidine, and down-regulated by VIP. Overall, the regulation of di / tri-peptide transport may be contributed to 1) changes in apical proton-motive force 2) recruitment of di / tri-peptide transporters from vesicular storages 3) changes in gene transcription / mRNA stability. The aim of the present review is to discuss physiological, patho-physiological and druginduced regulation of di / tri-peptide transporter mediated transport.
Export Options
About this article
Cite this article as:
Nielsen U. C. and Brodin B., Di / tri-Peptide Transporters as Drug Delivery Targets: Regulation of Transport Under Physiological and Patho-physiological Conditions, Current Drug Targets 2003; 4 (5) . https://dx.doi.org/10.2174/1389450033491028
DOI https://dx.doi.org/10.2174/1389450033491028 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Insulin Management for Type 1 Diabetic Patients During Social Alcohol Consumption: The SPRITZ Study
Current Diabetes Reviews Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
Current Neurovascular Research Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design The Coronary Collateral Circulation in Man
Current Cardiology Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Various Cell Therapy Approaches for Bone Diseases in the Controlled Clinical Trials: A Systematic Review and Meta-analysis Study
Current Stem Cell Research & Therapy Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Treatment of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews A Simple Stability-Indicating LC-UV Method to Assay Sitagliptin Phosphate in Tablets
Current Analytical Chemistry